[Renal transplantation].
Recent immunosuppressive drugs, including mycophenolate mofetil and basiliximab in addition to calcineurin inhibitors, have reduced the incidence and severity of acute allograft rejection in kidney transplants. This article introduces newly developed agents such as CTLA4-Ig, LEA29Y, rituximab, and FTY720 and also reviews immunosuppressive protocols which withdraw steroid or calcineurin inhibitors. Unrelated or ABO incompatible living donor kidney transplants have increased due to advancement of immunosuppressive